Peptide derivatives of three distinct lipopolysaccharide binding proteins inhibit lipopolysaccharide-induced tumor necrosis factor-alpha secretion in vitro

Richard J Battafarano, Peters S. Dahlberg, Craig A. Ratz, Jennifer W. Johnstom, Beulah H. Gray, Judith R. Haseman, Kevin H. Mayo, David L. Dunn

Research output: Contribution to journalArticle

Abstract

Background. Bactericidal permeability increasing protein (BPI), Limulus anti-lipopolysaccharide factor (LALF), and lipopolysaccharide binding protein (LBP) are three distinct proteins that bind to lipopolysaccharide (LPS). Intriguingly, binding of BPI and LALF to LPS results in neutralization of LPS activity, whereas the binding of LBP to LPS creates a complex that results in augmentation of LPS activity. Despite their different effector functions, we hypothesized that peptides based on the sequences of the proposed LPS-binding motif from each protein would neutralize LPS in vitro. Methods. Three peptide sequences, each 27 amino acids in length, of the proposed LPS-binding motif of BPI (BG38), LALF (BG42), and LBP (BG43) were synthesized. These peptides were then tested for their: (1) ability to inhibit macrophage secretion of TNF-α after stimulation by LPS derived from Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Serratia marcescens; and (2) bactericidal activity against these same four gram-negative bacteria in vitro. Results. Synthetic peptides BG38 (BPI-derived), BG42 (LALF-derived), and BG43 (LBP-derived) but not control peptide significantly inhibited LPS-induced tumor necrosis factor-α secretion by macrophages and mediated the lysis of gram-negative bacteria in vitro. In addition, preincubation of LPS with peptide BG38 mediated complete protection subsequent to lethal endotoxin challenge. Conclusions. These data demonstrate that small peptides derived from BPI, LALF, and LBP retained significant endotoxin-netralizing and bactericidal activity against many different gram-negative bacteria in vitro. Identification of this conserved LPS-binding region within each protein may aid in the development of new immunomodulatory reagents for use as adjuvant therapy in the treatment of gram-negative bacterial sepsis.

Original languageEnglish (US)
Pages (from-to)318-324
Number of pages7
JournalSurgery
Volume118
Issue number2
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Lipopolysaccharides
Tumor Necrosis Factor-alpha
Peptides
Gram-Negative Bacteria
Endotoxins
lipopolysaccharide-binding protein
In Vitro Techniques
Macrophages
Serratia marcescens
Amino Acid Motifs
Klebsiella pneumoniae
Pseudomonas aeruginosa
Sepsis
Proteins
bactericidal permeability increasing protein
antilipopolysaccharide factor (Limulus)
Escherichia coli
Amino Acids

ASJC Scopus subject areas

  • Surgery

Cite this

Peptide derivatives of three distinct lipopolysaccharide binding proteins inhibit lipopolysaccharide-induced tumor necrosis factor-alpha secretion in vitro. / Battafarano, Richard J; Dahlberg, Peters S.; Ratz, Craig A.; Johnstom, Jennifer W.; Gray, Beulah H.; Haseman, Judith R.; Mayo, Kevin H.; Dunn, David L.

In: Surgery, Vol. 118, No. 2, 1995, p. 318-324.

Research output: Contribution to journalArticle

Battafarano, Richard J ; Dahlberg, Peters S. ; Ratz, Craig A. ; Johnstom, Jennifer W. ; Gray, Beulah H. ; Haseman, Judith R. ; Mayo, Kevin H. ; Dunn, David L. / Peptide derivatives of three distinct lipopolysaccharide binding proteins inhibit lipopolysaccharide-induced tumor necrosis factor-alpha secretion in vitro. In: Surgery. 1995 ; Vol. 118, No. 2. pp. 318-324.
@article{cfa58c1ef0bd4a488500ba93a2cf8cf4,
title = "Peptide derivatives of three distinct lipopolysaccharide binding proteins inhibit lipopolysaccharide-induced tumor necrosis factor-alpha secretion in vitro",
abstract = "Background. Bactericidal permeability increasing protein (BPI), Limulus anti-lipopolysaccharide factor (LALF), and lipopolysaccharide binding protein (LBP) are three distinct proteins that bind to lipopolysaccharide (LPS). Intriguingly, binding of BPI and LALF to LPS results in neutralization of LPS activity, whereas the binding of LBP to LPS creates a complex that results in augmentation of LPS activity. Despite their different effector functions, we hypothesized that peptides based on the sequences of the proposed LPS-binding motif from each protein would neutralize LPS in vitro. Methods. Three peptide sequences, each 27 amino acids in length, of the proposed LPS-binding motif of BPI (BG38), LALF (BG42), and LBP (BG43) were synthesized. These peptides were then tested for their: (1) ability to inhibit macrophage secretion of TNF-α after stimulation by LPS derived from Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Serratia marcescens; and (2) bactericidal activity against these same four gram-negative bacteria in vitro. Results. Synthetic peptides BG38 (BPI-derived), BG42 (LALF-derived), and BG43 (LBP-derived) but not control peptide significantly inhibited LPS-induced tumor necrosis factor-α secretion by macrophages and mediated the lysis of gram-negative bacteria in vitro. In addition, preincubation of LPS with peptide BG38 mediated complete protection subsequent to lethal endotoxin challenge. Conclusions. These data demonstrate that small peptides derived from BPI, LALF, and LBP retained significant endotoxin-netralizing and bactericidal activity against many different gram-negative bacteria in vitro. Identification of this conserved LPS-binding region within each protein may aid in the development of new immunomodulatory reagents for use as adjuvant therapy in the treatment of gram-negative bacterial sepsis.",
author = "Battafarano, {Richard J} and Dahlberg, {Peters S.} and Ratz, {Craig A.} and Johnstom, {Jennifer W.} and Gray, {Beulah H.} and Haseman, {Judith R.} and Mayo, {Kevin H.} and Dunn, {David L.}",
year = "1995",
doi = "10.1016/S0039-6060(05)80340-X",
language = "English (US)",
volume = "118",
pages = "318--324",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Peptide derivatives of three distinct lipopolysaccharide binding proteins inhibit lipopolysaccharide-induced tumor necrosis factor-alpha secretion in vitro

AU - Battafarano, Richard J

AU - Dahlberg, Peters S.

AU - Ratz, Craig A.

AU - Johnstom, Jennifer W.

AU - Gray, Beulah H.

AU - Haseman, Judith R.

AU - Mayo, Kevin H.

AU - Dunn, David L.

PY - 1995

Y1 - 1995

N2 - Background. Bactericidal permeability increasing protein (BPI), Limulus anti-lipopolysaccharide factor (LALF), and lipopolysaccharide binding protein (LBP) are three distinct proteins that bind to lipopolysaccharide (LPS). Intriguingly, binding of BPI and LALF to LPS results in neutralization of LPS activity, whereas the binding of LBP to LPS creates a complex that results in augmentation of LPS activity. Despite their different effector functions, we hypothesized that peptides based on the sequences of the proposed LPS-binding motif from each protein would neutralize LPS in vitro. Methods. Three peptide sequences, each 27 amino acids in length, of the proposed LPS-binding motif of BPI (BG38), LALF (BG42), and LBP (BG43) were synthesized. These peptides were then tested for their: (1) ability to inhibit macrophage secretion of TNF-α after stimulation by LPS derived from Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Serratia marcescens; and (2) bactericidal activity against these same four gram-negative bacteria in vitro. Results. Synthetic peptides BG38 (BPI-derived), BG42 (LALF-derived), and BG43 (LBP-derived) but not control peptide significantly inhibited LPS-induced tumor necrosis factor-α secretion by macrophages and mediated the lysis of gram-negative bacteria in vitro. In addition, preincubation of LPS with peptide BG38 mediated complete protection subsequent to lethal endotoxin challenge. Conclusions. These data demonstrate that small peptides derived from BPI, LALF, and LBP retained significant endotoxin-netralizing and bactericidal activity against many different gram-negative bacteria in vitro. Identification of this conserved LPS-binding region within each protein may aid in the development of new immunomodulatory reagents for use as adjuvant therapy in the treatment of gram-negative bacterial sepsis.

AB - Background. Bactericidal permeability increasing protein (BPI), Limulus anti-lipopolysaccharide factor (LALF), and lipopolysaccharide binding protein (LBP) are three distinct proteins that bind to lipopolysaccharide (LPS). Intriguingly, binding of BPI and LALF to LPS results in neutralization of LPS activity, whereas the binding of LBP to LPS creates a complex that results in augmentation of LPS activity. Despite their different effector functions, we hypothesized that peptides based on the sequences of the proposed LPS-binding motif from each protein would neutralize LPS in vitro. Methods. Three peptide sequences, each 27 amino acids in length, of the proposed LPS-binding motif of BPI (BG38), LALF (BG42), and LBP (BG43) were synthesized. These peptides were then tested for their: (1) ability to inhibit macrophage secretion of TNF-α after stimulation by LPS derived from Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Serratia marcescens; and (2) bactericidal activity against these same four gram-negative bacteria in vitro. Results. Synthetic peptides BG38 (BPI-derived), BG42 (LALF-derived), and BG43 (LBP-derived) but not control peptide significantly inhibited LPS-induced tumor necrosis factor-α secretion by macrophages and mediated the lysis of gram-negative bacteria in vitro. In addition, preincubation of LPS with peptide BG38 mediated complete protection subsequent to lethal endotoxin challenge. Conclusions. These data demonstrate that small peptides derived from BPI, LALF, and LBP retained significant endotoxin-netralizing and bactericidal activity against many different gram-negative bacteria in vitro. Identification of this conserved LPS-binding region within each protein may aid in the development of new immunomodulatory reagents for use as adjuvant therapy in the treatment of gram-negative bacterial sepsis.

UR - http://www.scopus.com/inward/record.url?scp=0029087339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029087339&partnerID=8YFLogxK

U2 - 10.1016/S0039-6060(05)80340-X

DO - 10.1016/S0039-6060(05)80340-X

M3 - Article

C2 - 7638748

AN - SCOPUS:0029087339

VL - 118

SP - 318

EP - 324

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 2

ER -